Monolom India Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.30 Cr
as on 16-11-2024
- Paid Up Capital ₹ 3.44 Cr
as on 16-11-2024
- Company Age 7 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 50.00 K
as on 16-11-2024
- Revenue 8.30%
(FY 2023)
- Profit 20.21%
(FY 2023)
- Ebitda 14.82%
(FY 2023)
- Net Worth 20.48%
(FY 2023)
- Total Assets 7.97%
(FY 2023)
About Monolom India Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.30 Cr and a paid-up capital of Rs 3.44 Cr.
The company currently has active open charges totaling ₹50,000.00.
Sreenivasan Nidichenametla, Chiara Bergerone, and Ben Dolitzky serve as directors at the Company.
- CIN/LLPIN
U24303PN2017FTC188118
- Company No.
188118
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
27 Oct 2017
- Date of AGM
27 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Monolom India Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sreenivasan Nidichenametla  | Director | 02-Aug-2022 | Current |
Chiara Bergerone  | Director | Current | |
Ben Dolitzky  | Director | 24-Mar-2023 | Current |
Financial Performance of Monolom India Pharma.
Monolom India Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 8.3% increase. The company also saw a substantial improvement in profitability, with a 20.21% increase in profit. The company's net worth Soared by an impressive increase of 20.48%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Monolom India Pharma?
In 2023, Monolom India Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vanamali Organics Private LimitedActive 11 years 10 monthsSreenivasan Nidichenametla and Chiara Bergerone are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Hongkong And Shanghai Banking Corporation Limited Creation Date: 23 Nov 2022 | ₹0.05 M | Open |
How Many Employees Work at Monolom India Pharma?
Monolom India Pharma has a workforce of 39 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Monolom India Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Monolom India Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
